Annette K. Larsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Annette K. Larsen has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Andrzej Skladanowski
Ecole Normale Supe ´rieure Cachan Laboratory of Biology and Pharmacogenetics of Human Tumors 8113 Centre National de la Recherche Scientifique Unite ´Mixte Recherche Institut Gustave-Roussy France
6 shared publications- Alexandre E. Escargueil
Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, F-75012, Paris, France
3 shared publications A Skladanowski
2 shared publicationsC Gilbert
2 shared publicationsCéline Gobert
Institut Gustave-Roussy
2 shared publicationsJ Markovits
2 shared publications
Latest Publications
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 443
Feasibility of combining EGFR- and VEGF(R)-targeted agents in colorectal cancer.
443 Background: The extensive cross-talk between EGFR and VEGF(R) argues for joint targeting of the two signaling pathways. Unexpectedly, large clinical trials with combinations of EGFR-targeted antibodies and bevacizumab, a VEGF-blocking antibody, showed no added benefit in colorectal cancer (CRC) patients compared to bevacizumab alone. One difference between the antibodies and the small molecule tyrosine kinase inhibitors (TKIs) is the potential of the TKIs to inhibit intracellular signaling pathways. Methods: We here characterize the activity of two TKIs, the irreversible EGFR/HER2 inhibitor BIBW2992 (B2) and the VEGFR/PDGFR/FGFR inhibitor BIBF1120 (B1) toward human CRC models in vitro and in vivo. Results: B1 and B2 together showed strong activity toward HT-29 CRC xenografts, compared to either drug alone, and was associated with increased tumor cell death. In comparison, cetuximab and bevacizumab together were no more active than either drug alone and showed exclusively cytostatic activity. Recent findings provide evidence for intracellular VEGF-signaling in epithelial tumors which synergizes with EGFR for proliferation and survival (Cell 140:268, 2010). In agreement, HT-29 tumors expressed abundant intracellular VEGFR1 as shown by immunohistochemistry. Furthermore, targeted knock-down of VEGFR1 in cellular models was accompanied by increased sensitivity to B1 and B2 combinations thereby confirming the relevance of intracellular VEGFR1 signaling for CRC survival. Conclusions: Combinations of B1 and B2 show synergistic activity in CRC models. These findings favor clinical studies with combinations of the two agents and suggest that rationally selected EGFR- and VEGF-targeted agents can be combined for clinical benefit. [Table: see text]
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4) , 443
Feasibility of combining EGFR- and VEGF(R)-targeted agents in colorectal cancer.
443 Background: The extensive cross-talk between EGFR and VEGF(R) argues for joint targeting of the two signaling pathways. Unexpectedly, large clinical trials with combinations of EGFR-targeted antibodies and bevacizumab, a VEGF-blocking antibody, showed no added benefit in colorectal cancer (CRC) patients compared to bevacizumab alone. One difference between the antibodies and the small molecule tyrosine kinase inhibitors (TKIs) is the potential of the TKIs to inhibit intracellular signaling pathways. Methods: We here characterize the activity of two TKIs, the irreversible EGFR/HER2 inhibitor BIBW2992 (B2) and the VEGFR/PDGFR/FGFR inhibitor BIBF1120 (B1) toward human CRC models in vitro and in vivo. Results: B1 and B2 together showed strong activity toward HT-29 CRC xenografts, compared to either drug alone, and was associated with increased tumor cell death. In comparison, cetuximab and bevacizumab together were no more active than either drug alone and showed exclusively cytostatic activity. Recent findings provide evidence for intracellular VEGF-signaling in epithelial tumors which synergizes with EGFR for proliferation and survival (Cell 140:268, 2010). In agreement, HT-29 tumors expressed abundant intracellular VEGFR1 as shown by immunohistochemistry. Furthermore, targeted knock-down of VEGFR1 in cellular models was accompanied by increased sensitivity to B1 and B2 combinations thereby confirming the relevance of intracellular VEGFR1 signaling for CRC survival. Conclusions: Combinations of B1 and B2 show synergistic activity in CRC models. These findings favor clinical studies with combinations of the two agents and suggest that rationally selected EGFR- and VEGF-targeted agents can be combined for clinical benefit. [Table: see text]
- Open Access
- 1 October 2004
- Published by Elsevier in Molecular Pharmacology
- Vol. 66 (4) , 1035-1042
The Antitumor Triazoloacridone C-1305 Is a Topoisomerase II Poison with Unusual Properties
C-1305 [S-[[3-(dimethylamino)propyl]amino]-8-hydroxy-6H-v-triazolo[4,5,1-de]acridin-6-one] is a triazoloacridone with excellent activity in colon cancer models. The mechanism of C-1305 is unknown, although similarities in the chemical structure between C-1305 and amsacrine suggest common cellular targets. Here, we report that C-1305 is a topoisomerase II poison that is able to induce cleavable complexes with topoisomerase II in vitro as well as in living cells. Even at optimal concentrations, C-1305 is a much weaker inducer of cleavable complexes than amsacrine. Because the cytotoxic activities of the two compounds after continuous drug exposure are comparable, these findings suggest that the low levels of cleavable complexes induced by C-1305 may be unusually toxic. In contrast to amsacrine, the cytotoxicity of C-1305 is strongly time-dependent, with at least 24 h of drug exposure required for optimal cytotoxicity. The p53 tumor suppressor is inactivated in the majority of human tumors, including colorectal cancers. We therefore compared the long-term cytotoxic effects of C-1305, amsacrine, and doxorubicin on human cell lines in which the p53 or p21 pathways have been specifically disrupted by targeted homologous recombination. Disruption of p53 and p21 had minor influence on the cytotoxicity of doxorubicin, whereas p53 but not p21 disruption was associated with increased resistance to amsacrine. In marked contrast, disruption of p53 and p21 was associated with increased sensitivity to C-1305. Taken together, our results show that exposure to C-1305 is accompanied by the formation of low levels of potent cleavable complexes that are selectively toxic toward tumor cells with defective p53 function.
- 1 October 2004
- Published by Elsevier in Molecular Pharmacology
- Vol. 66 (4) , 1035-1042
Open AccessThe Antitumor Triazoloacridone C-1305 Is a Topoisomerase II Poison with Unusual Properties
C-1305 [S-[[3-(dimethylamino)propyl]amino]-8-hydroxy-6H-v-triazolo[4,5,1-de]acridin-6-one] is a triazoloacridone with excellent activity in colon cancer models. The mechanism of C-1305 is unknown, although similarities in the chemical structure between C-1305 and amsacrine suggest common cellular targets. Here, we report that C-1305 is a topoisomerase II poison that is able to induce cleavable complexes with topoisomerase II in vitro as well as in living cells. Even at optimal concentrations, C-1305 is a much weaker inducer of cleavable complexes than amsacrine. Because the cytotoxic activities of the two compounds after continuous drug exposure are comparable, these findings suggest that the low levels of cleavable complexes induced by C-1305 may be unusually toxic. In contrast to amsacrine, the cytotoxicity of C-1305 is strongly time-dependent, with at least 24 h of drug exposure required for optimal cytotoxicity. The p53 tumor suppressor is inactivated in the majority of human tumors, including colorectal cancers. We therefore compared the long-term cytotoxic effects of C-1305, amsacrine, and doxorubicin on human cell lines in which the p53 or p21 pathways have been specifically disrupted by targeted homologous recombination. Disruption of p53 and p21 had minor influence on the cytotoxicity of doxorubicin, whereas p53 but not p21 disruption was associated with increased resistance to amsacrine. In marked contrast, disruption of p53 and p21 was associated with increased sensitivity to C-1305. Taken together, our results show that exposure to C-1305 is accompanied by the formation of low levels of potent cleavable complexes that are selectively toxic toward tumor cells with defective p53 function.
- 1 August 2003
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 99 (2) , 167-181
Catalytic topoisomerase II inhibitors in cancer therapy
- 1 August 2003
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 99 (2) , 167-181
Catalytic topoisomerase II inhibitors in cancer therapy
- Open Access
- 17 August 2001
- Published by Wiley in The FASEB Journal
- Vol. 15 (12) , 1-22
Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling
Although initiation of chromosome condensation during early prophase is linked temporally to the appearance of the mitotic cdc2 kinase in the nucleus, it is not known what targets the kinase to the nucleus and how this is coupled to chromatin remodeling. We now report that cdc2 kinase forms stable molecular complexes with the nuclear enzyme DNA topoisomerase II, which is associated with marked stimulation of both DNA binding and catalytic activity of topoisomerase II, albeit in a phosphorylation‐independent manner. The molecular interaction is required for recruitment of cdc2 kinase, as shown by incubation of purified enzymes with chicken erythrocyte nuclei, which have neither endogenous topoisomerase II nor cdc2 kinase. The physical association between the two enzymes alters the DNA/topoisomerase II interaction as shown by pulse‐field electrophoresis after incubation of intact nuclei with the specific topoisomerase II inhibitor VM‐26. Furthermore, the presence of both enzymes, but not either enzyme alone, is accompanied by extensive chromatin remodeling converting the interphase nuclei into precondensation chromosomes with striking resemblance to early prophase structures. Our results reveal a novel property of cyclin‐dependent kinases and demonstrate that the recruitment of cdc2 kinase by topoisomerase II is coupled to chromatin remodeling.
- 17 August 2001
- Published by Wiley in The FASEB Journal
- Vol. 15 (12) , 1-22
Open AccessRecruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling
Although initiation of chromosome condensation during early prophase is linked temporally to the appearance of the mitotic cdc2 kinase in the nucleus, it is not known what targets the kinase to the nucleus and how this is coupled to chromatin remodeling. We now report that cdc2 kinase forms stable molecular complexes with the nuclear enzyme DNA topoisomerase II, which is associated with marked stimulation of both DNA binding and catalytic activity of topoisomerase II, albeit in a phosphorylation‐independent manner. The molecular interaction is required for recruitment of cdc2 kinase, as shown by incubation of purified enzymes with chicken erythrocyte nuclei, which have neither endogenous topoisomerase II nor cdc2 kinase. The physical association between the two enzymes alters the DNA/topoisomerase II interaction as shown by pulse‐field electrophoresis after incubation of intact nuclei with the specific topoisomerase II inhibitor VM‐26. Furthermore, the presence of both enzymes, but not either enzyme alone, is accompanied by extensive chromatin remodeling converting the interphase nuclei into precondensation chromosomes with striking resemblance to early prophase structures. Our results reveal a novel property of cyclin‐dependent kinases and demonstrate that the recruitment of cdc2 kinase by topoisomerase II is coupled to chromatin remodeling.
- 1 April 2001
- Vol. 61 (7) , 2961-7
Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
BN 80915 is the lead compound from a novel class of E-ring modified camptothecin analogues, the homocamptothecins, which show potent antitumor activities in animal models. Here, we report that BN 80915 induces up to 2-fold more cleavable complexes between plasmid DNA and purified human topoisomerase I than SN-38 and camptothecin. BN 80915 also induces DNA-topoisomerase I complexes in living HT-29 colon carcinoma cells, as shown by the in vivo link assay. BN 80915 is an extremely potent inducer of DNA-protein complexes in these cells starting at a concentration of 5 nM in the media. BN 80915 is clearly more potent than SN-38, because at least 20 times more SN-38 is needed to induce comparable levels of cleavable complexes. Kinetic experiments show that BN 80915 induces cleavable complexes within minutes that remain stable for at least 6 h in the presence of drug. Whereas the majority of the complexes are reversed within 15 min after drug removal, a substantial fraction (30%) persists for at least 4 h, in contrast with SN-38-treated cells, where all complexes have disappeared by this time. BN 80915 shows strong antiproliferative effects toward HT-29 cells with an IC50 of 0.3 nM compared with 20 nM for SN-38 and 40 nM for topotecan. BN 80915 is also potent against other colon carcinoma cells as well as toward cells growing in three dimensions as multicellular spheroids. HL-60 cells expressing functional P-glycoprotein or multidrug resistance protein show no cross-resistance toward BN 80915. Taken together, our results show that BN 80915 is unusually potent toward human colon carcinoma cells because of the formation of high levels of stable, covalent DNA-topoisomerase complexes.
- 1 April 2001
- Vol. 61 (7) , 2961-7
Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
BN 80915 is the lead compound from a novel class of E-ring modified camptothecin analogues, the homocamptothecins, which show potent antitumor activities in animal models. Here, we report that BN 80915 induces up to 2-fold more cleavable complexes between plasmid DNA and purified human topoisomerase I than SN-38 and camptothecin. BN 80915 also induces DNA-topoisomerase I complexes in living HT-29 colon carcinoma cells, as shown by the in vivo link assay. BN 80915 is an extremely potent inducer of DNA-protein complexes in these cells starting at a concentration of 5 nM in the media. BN 80915 is clearly more potent than SN-38, because at least 20 times more SN-38 is needed to induce comparable levels of cleavable complexes. Kinetic experiments show that BN 80915 induces cleavable complexes within minutes that remain stable for at least 6 h in the presence of drug. Whereas the majority of the complexes are reversed within 15 min after drug removal, a substantial fraction (30%) persists for at least 4 h, in contrast with SN-38-treated cells, where all complexes have disappeared by this time. BN 80915 shows strong antiproliferative effects toward HT-29 cells with an IC50 of 0.3 nM compared with 20 nM for SN-38 and 40 nM for topotecan. BN 80915 is also potent against other colon carcinoma cells as well as toward cells growing in three dimensions as multicellular spheroids. HL-60 cells expressing functional P-glycoprotein or multidrug resistance protein show no cross-resistance toward BN 80915. Taken together, our results show that BN 80915 is unusually potent toward human colon carcinoma cells because of the formation of high levels of stable, covalent DNA-topoisomerase complexes.
- 1 March 2000
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 85 (3) , 217-229
Resistance mechanisms associated with altered intracellular distribution of anticancer agents
- 1 March 2000
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 85 (3) , 217-229
Resistance mechanisms associated with altered intracellular distribution of anticancer agents
- 1 September 1999
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 5 (3) , 171-178
DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?
Mammalian DNA topoisomerase I is a multifunctional enzyme which is essential for embryonal development. In addition to its classical DNA nick-ing-closing activities which are needed for relaxation of...
- 1 September 1999
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 5 (3) , 171-178
DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?
Mammalian DNA topoisomerase I is a multifunctional enzyme which is essential for embryonal development. In addition to its classical DNA nick-ing-closing activities which are needed for relaxation of...
- 31 August 1999
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (18) , 10355-10360
The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53
DNA topoisomerase I is a nuclear enzyme involved in transcription, recombination, and DNA damage recognition. Previous studies have shown that topoisomerase I interacts directly with the tumor-suppressor protein p53. p53 is a transcription factor that activates certain genes through binding to specific DNA sequences. We now report that topoisomerase I can be stimulated by both latent and activated wild-type p53 as well as by several mutant and truncated p53 proteins in vitro , indicating that sequence-specific DNA-binding and stimulation of topoisomerase I are distinct properties of p53. These assays also suggest that the binding site for topoisomerase I on p53 is between amino acids 302 and 321. In living cells, the interaction between p53 and topoisomerase I is strongly dependent on p53 status. In MCF-7 cells, which have wild-type p53, the association between the two proteins is tightly regulated in a spatial and temporal manner and takes place only during brief periods of genotoxic stress. In marked contrast, the two proteins are constitutively associated in HT-29 cells, which have mutant p53. These findings have important implications for both cellular stress response and genomic stability, given the ability of topoisomerase I to recognize DNA lesions as well as to cause illegitimate recombination.
- 31 August 1999
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (18) , 10355-10360
The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53
DNA topoisomerase I is a nuclear enzyme involved in transcription, recombination, and DNA damage recognition. Previous studies have shown that topoisomerase I interacts directly with the tumor-suppressor protein p53. p53 is a transcription factor that activates certain genes through binding to specific DNA sequences. We now report that topoisomerase I can be stimulated by both latent and activated wild-type p53 as well as by several mutant and truncated p53 proteins in vitro , indicating that sequence-specific DNA-binding and stimulation of topoisomerase I are distinct properties of p53. These assays also suggest that the binding site for topoisomerase I on p53 is between amino acids 302 and 321. In living cells, the interaction between p53 and topoisomerase I is strongly dependent on p53 status. In MCF-7 cells, which have wild-type p53, the association between the two proteins is tightly regulated in a spatial and temporal manner and takes place only during brief periods of genotoxic stress. In marked contrast, the two proteins are constitutively associated in HT-29 cells, which have mutant p53. These findings have important implications for both cellular stress response and genomic stability, given the ability of topoisomerase I to recognize DNA lesions as well as to cause illegitimate recombination.
- 1 October 1998
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
- Vol. 1400 (1-3) , 257-274
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death
- 1 October 1998
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
- Vol. 1400 (1-3) , 257-274
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death
- 30 June 1998
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 45 (2) , 535-544
DNA topoisomerases as repair enzymes: mechanism(s) of action and regulation by p53.
DNA topoisomerases regulate the organization of DNA and are important targets for many clinically used antineoplastic agents. In addition, DNA topoisomerases modulate the cellular sensitivity toward a number of DNA damaging agents. Increased topoisomerase II activities were shown to contribute to the resistance of both nitrogen mustard- and cisplatin-resistant cells. Similarly, cells with decreased topoisomerase II levels show increased sensitivity to cisplatin, carmustine, mitomycin C and nitrogen mustard. Recent studies propose that topoisomerases may be involved in damage recognition and DNA repair at several different levels including: 1) the initial recognition of DNA lesions; 2) DNA recombination; and 3) regulation of DNA structure. The stress-activated oncogene suppressor protein p53 can modulate the activity of at least three different human topoisomerases, either directly by molecular associations or by transcriptional regulation. Since DNA topoisomerases have considerable recombinase activities, inappropriately activated topoisomerases in tumor cells lacking functional p53 may contribute to the genetic instability of these cells.
- 30 June 1998
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 45 (2) , 535-544
DNA topoisomerases as repair enzymes: mechanism(s) of action and regulation by p53.
DNA topoisomerases regulate the organization of DNA and are important targets for many clinically used antineoplastic agents. In addition, DNA topoisomerases modulate the cellular sensitivity toward a number of DNA damaging agents. Increased topoisomerase II activities were shown to contribute to the resistance of both nitrogen mustard- and cisplatin-resistant cells. Similarly, cells with decreased topoisomerase II levels show increased sensitivity to cisplatin, carmustine, mitomycin C and nitrogen mustard. Recent studies propose that topoisomerases may be involved in damage recognition and DNA repair at several different levels including: 1) the initial recognition of DNA lesions; 2) DNA recombination; and 3) regulation of DNA structure. The stress-activated oncogene suppressor protein p53 can modulate the activity of at least three different human topoisomerases, either directly by molecular associations or by transcriptional regulation. Since DNA topoisomerases have considerable recombinase activities, inappropriately activated topoisomerases in tumor cells lacking functional p53 may contribute to the genetic instability of these cells.